FLT3 and acute myeloid leukemia: In another study, Daver et al. examined elderly patients with AML (≥65 years old) with NPM1 (146 patients) and FLT3 testing (388 patients).43 While neither mutation alone showed statistically significant impact on OS in the elderly AML cohort, the NPM1-mutated/FLT3-wild type subset (14 patients) showed extended OS (21.5 months) compared to all others (9.0 months).